BD Veritor™ Plus System
for Rapid Detection of
Flu A+B

The BD Veritor™ Plus System test for Flu A and Flu B that is simple, efficient, and fast.

 

Contact Us

 

BD Veritor All Assays

Overcome the challenges of flu season.

The BD Veritor™ Plus System offers simple operation, an efficient workflow, and fast, traceable results, which may help improve the patient experience.

White and orange packing box with blue lettering for BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 & Flu A+B test

BD Veritor™ Plus System for Rapid Detection of Flu A+B (CLIA-waived kit) offers proven performance vs PCR

 

PPA†

NPA*

Results in

Influenza A

CLIA-waived

83.6%

(76.1%, 89.1%)

97.5%

(95.7%, 98.5%)

 

10 minutes

 

Influenza B

CLIA-waived

81.3%

 (71.1%, 88.5%)

98.2%

(95.7%, 99.3%)

10 minutes

 

Flu A+B results in 10 minutes

†positive percent agreement

‡negative percent agreement

 

Ordering information

Cat no.

Qty

BD Veritor™ Plus System Flu A+B CLIA-waived kit

256045

30 tests

BD Veritor™ Plus System Flu A+B moderately complex kit

256041

30 tests

Get more answers with every sample.

Content Card Image

Simplifies the testing process

  • Helps user operation with single-button functionality that can potentially reduce manual test processing errors
  • Provides intuitive sample processing with prefilled, unitized tubes
Content Card Image

Delivers workflow efficiency

Adapts easily to your workflow by offering 2 operational modes

  • Walk Away: the test device is inserted into the Analyzer immediately after preparation, allowing staff to multitask while the sample incubates
  • Analyze Now: the test device is inserted after the incubation time is complete, allowing batches of samples to be tested at once
Content Card Image

Provides results traceability

  • Stores or downloads the lot number, patient/ specimen ID, operator ID and test records using the BD Veritor™ InfoWiFi module or via the companion ImageMover application
  • Offers result printing capabilities via USB port
Content Card Image

Achieves reliable, rapid results

  • Displays easy-to-read digital results for flu in just 10 minutes1
  • Provides clear, objective results by correcting for nonspecific binding and detecting faint lines not recognized by the unaided eye4

Contact a Sales Representative to get your organization’s

diagnostic testing program started today

How It Works

The BD Veritor™ Plus System provides an easy sample-collection process that can be incorporated across a variety of clinical settings.

Content Card Image

Step 1: Collect sample

Content Card Image

Step 2: Mix the swab with the reagent vial

Content Card Image

Step 3: Prepare assay with the sample

Content Card Image

Step 4: Run the test

Content Card Image

Step 5: Insert the cartridge and read the results

BD Veritor™ Plus System Support & Training

See how BD supports you with tools, education, and training—enabling a streamlined point-of-care experience for those you serve, and confidence in your results.

Reimbursement May Be Available Now

Your questions about reimbursement, answered.

1. BD Veritor™ Plus System for Rapid Detection of Flu A+B. Package insert. 8087667 Becton, Dickinson and Company.

BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152-0999 USA 800-638-8663

*EUA Information for the BD Veritor™ SARS-CoV-2 and SARS-CoV-2 & Flu A+B assays: These products have not been FDA cleared or approved; but have been authorized by FDA under EUA for use by authorized laboratories. The BD Veritor™ System for Rapid Detection of SARS-CoV-2 has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, the emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.